EVMN — Evommune, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2044725 ·
Last close
$6.41
Market Cap
$232.63M
52W High
$33.20
52W Low
$6.02
ADV30
884,115
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -34,895,000 | -32,246,000 | 301,947,000 | 60,034,000 | 24,361,000 |
| Mar 2026 | 0 | — | -23,954,000 | -21,674,000 | 322,455,000 | 48,318,000 | 17,900,000 |
| Dec 2025 | 0 | — | -29,716,000 | -28,273,000 | 224,946,000 | 44,063,000 | 19,380,000 |
| Sep 2025 | 10,000,000 | — | -13,328,000 | -12,475,000 | 84,544,000 | 26,818,000 | 267,681,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,153,000
Investing CF
$-200,872,000
Financing CF
$274,217,000
CapEx
$-370,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-275,009,000
Inventory
—
Receivables
—
ST Investments
$140,759,000
EBIT TTM
$-101,893,000
Pretax Income TTM
$-94,668,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,000,000
EBITDA
$-100,356,000
Free Cash Flow
$-39,127,752
Enterprise Value
$190,354,864
Total Cash
$200,792,992
Total Debt
$8,629,000
Shares Out
36,292,113
Trailing EPS
$-11.82
Book Value
$7.65
ROE
-52.1%
ROA
-32.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,000,000 | -81,071,000 | -68,870,000 | 224,946,000 | 19,380,000 | 205,566,000 | -76,441,000 |
| Dec 2024 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$322,455,000
Forward EPS
$-3.39
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $6.41 · call volume: 17 · put volume: 142
Expected Move to 2027-02-19:
±$2.65
(41.34%) —
implied range
$3.76 –
$9.06
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CAMP | Camp4 Therapeutics Corp | $232.19M | $3.70 | — |
| KROS | Keros Therapeutics, Inc. | $230.79M | $11.64 | — |
| SLGL | Sol-Gel Technologies Ltd. | $230.29M | $70.34 | — |
| SIGA | SIGA TECHNOLOGIES INC | $235.67M | $3.28 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $237.63M | $2.51 | — |
News headlines (Yahoo Finance, 1h cache)
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
2026-10-01 12:00 · Yahoo
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
2026-09-23 20:05 · Yahoo
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
2026-09-16 19:55 · Yahoo
Evommune Halts Atopic Dermatitis Program Following Trial Failure
2026-09-09 11:40 · Yahoo
Why Is EVMN Stock Down 13% After-Hours?
2026-09-08 23:51 · Yahoo
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
2026-09-08 21:43 · Yahoo
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-06 20:05 · Yahoo
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
2026-07-30 12:00 · Yahoo
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
2026-06-30 15:15 · Yahoo
Evommune terminates oral drug’s development in CSU
2026-06-29 15:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.